Thumbnail
Access Restriction
Open

Author Onn, A. ♦ Tsuboi, M. ♦ Thatcher, N.
Source PubMed Central
Content type Text
Publisher Nature Publishing Group
File Format PDF
Date Created 2004-09-01
Copyright Year ©2004
Language English
Difficulty Level Medium
Subject Domain (in DDC) Technology ♦ Medicine & health ♦ Diseases
Subject Keyword Cancer Research ♦ Oncology
Abstract Worldwide, non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality and, until screening detects early disease, treatment for the majority of patients will consist of radiation therapy, chemotherapy or combinations thereof. Modern mono and doublet chemotherapy regimens have translated into modest increases in life expectancy and improved quality of life, but at the expense of systemic and pulmonary adverse events (AEs). There is a great unmet need to provide effective therapy for advanced NSCLC that does not have the toxicity burden of conventional chemotherapy and radiotherapy. Novel drugs that inhibit a range of growth factor receptors, such as the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib (‘Iressa’) and erlotinib (‘Tarceva’) or the monoclonal antibody cetuximab (‘Erbitux’), have recently been evaluated. Having demonstrated antitumour activity and rapid symptom improvement in pretreated patients with advanced NSCLC, gefitinib was approved in the USA, Japan and other countries. Gefitinib is well tolerated with a low incidence of grade 3/4 AEs. Interstitial lung disease has been reported in a small number of patients receiving gefitinib, although this may be attributed to other treatments and conditions. Nevertheless, although the use of novel treatments requires vigilance for unexpected AEs such as pulmonary toxicity, in this area of high unmet clinical need, the benefits outweigh the risks in patients for whom no other proven effective treatment exists.
ISSN 00070920
Age Range above 22 year
Educational Use Research
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2004-08-01
Rights Holder Nature Publishing Group
e-ISSN 15321827
Journal British Journal of Cancer
Volume Number 91
Issue Number Suppl 2
Starting Page 11


Open content in new tab

   Open content in new tab
Source: PubMed Central